Use of nk-1 receptor antagonists for treating mania

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 31/675 (2006.01) A61K 31/00 (2006.01) A61K 31/395 (2006.01) A61K 31/40 (2006.01) A61K 31/4035 (2006.01) A61K 31/404 (2006.01) A61K 31/435 (2006.01) A61K 31/438 (2006.01) A61K 31/445 (2006.01) A61K 31/451 (2006.01) A61K 31/4545 (2006.01) A61K 31/47 (2006.01) A61K 31/4709 (2006.01) A61K 31/5375 (2006.01) A61K 31/5377 (2006.01) A61K 45/06 (2006.01)

Patent

CA 2298777

The present invention provides the use of an orally active, long acting, CNS- penetrant NK-1 receptor antagonist, optionally with an antipsychotic agent, for the manufacture of a medicament for the treatment or prevention of mania or hypomania, methods of treatment using the NK-1 receptor antagonist and pharmaceutical compositions and products containing it.

La présente invention concerne l'utilisation d'un antagoniste du récepteur NK-1, pénétrant dans le SNC, à action prolongée, oralement actif, éventuellement avec un agent antipsychotique, pour produire un médicament destiné au traitement ou à la prévention de la manie ou de l'hypomanie, des méthodes de traitement utilisant l'antagoniste du récepteur NK-1, ainsi que des compositions et des produits pharmaceutiques le renfermant.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Use of nk-1 receptor antagonists for treating mania does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of nk-1 receptor antagonists for treating mania, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nk-1 receptor antagonists for treating mania will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1939499

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.